DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Daridorexant
Daridorexant
The Pharmacoeconomic Burden of Insomnia
Clinical Pharmacology of Daridorexant, a Novel Dual Orexin Receptor Antagonist
Rxoutlook® 4Th Quarter 2020
ACNP 59Th Annual Meeting: Poster Session I
Minutes of the CHMP Meeting 22-25 March 2021
A New Medication for Insomnia in Older Adults?
International Nonproprietary Names for Pharmaceutical Substances (INN)
ACNP 59Th Annual Meeting: Poster Session III
A New Dual Orexin Receptor Antagonist for the Treatment of Insomnia
Orexins/Hypocretins and Cancer: a Neuropeptide As Emerging Target
20 Years of Medicinal Chemistry Œ Always Look at the Bright Side
Reaching out for More
Lääkeaineiden Yleisnimet (INN-Nimet) 31.12.2019
Current and Emerging Therapies for Insomnia Mei T
Studies Toward the Synthesis of a Novel Diamine Scaffold
Insomnia in Patients with Psychiatric Disorders: Causes, Consequences, Best Practices, and Emerging Treatments
Idorsia Adds Insomnia to Its Pipeline Successes
Idorsia Business Report 2020
Top View
Effect of the New Dual Orexin Receptor Antagonist Daridorexant On
Download Pipeline Report
Nye Legemidler Som Ikke Har Markedsføringstillatelse for Legemidler Oppført På Listen Gjelder Retningslinjens Vilkår Uavhengig Av Indikasjon for Bruken
Annexes to the Annual Report of the European Medicines Agency 2020
FDA Accepts the New Drug Application for Review of Idorsia's Daridorexant
CHMP Agenda of the 19-22 July 2021 Meeting